Dear Khalid,

Beside well known prognostic Clinico-pathological markers for breast cancer in general (age, menopausal status, Tumor size, lymph node status, lymphovascular invasion, etc...) that guide general treatment decisions in breast cancer. Recently, there is an increased interest about level of Androgen Receptor expression, KI 67 index, CDH1 tumoral level, Tumor infiltrating lymphocytes, level of E-cdherin.

These markers are promising in identifying prognosis for triple negative breast cancer, however it should be noted these data are coming from retrospective studies and need proper prospective validation before being used in the normal day to day clinical practice.

http://meetinglibrary.asco.org/content/151689-156

ID4 would be another one

Thank you =D